20. November 2009 09:08
POZEN Inc. announced today the start of enrollment for the phase 3 studies for PA32540. PA32540 is a fixed-dose combination of 325 mg of enteric coated aspirin and 40 mg of immediate release omeprazole, under investigation for use in the secondary prevention of heart attacks and strokes in patients at risk for associated gastric ulcers.
[More]
20. November 2009 09:02
Genta Incorporated announced preliminary results that show a high objective response rate in a pilot study of patients with advanced melanoma that incorporates the Company’s lead oncology product, Genasense® (oblimersen sodium) Injection, administered for the first time as a 1-hour high-dose intravenous (IV) infusion.
[More]
4860eda6-fe31-4d8b-a8a6-7cc875daf80d|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Abraxane, Apoptosis, Bone, Cancer, Cell, Chemotherapy, Dacarbazine, DNA, Docetaxel, Evolution, Melanoma, Neutropenia, Oncology, Paclitaxel, Skin Cancer, Temozolomide
20. November 2009 08:52
Merck & Co., Inc. today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has recommended approval of ELONVA® (corifollitropin alfa injection) as a treatment in controlled ovarian stimulation (COS) in combination with a GnRH antagonist for the development of multiple follicles in women participating in an assisted reproductive technology (ART) program.
[More]
20. November 2009 06:39
Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today that a combination of its synthetic consensus H1N1, H2N2, H3N2, and H5N1 influenza vaccine candidates achieved protective antibody responses against several different influenza sub-types and strains in ferrets.
[More]
5ea790c2-653b-41a5-a70d-b25aa6cc161b|0|.0
Posted in: Drug Trial News | Pharmaceutical News
Tags: Antibody, Avian Influenza, Cancer, Cervical Cancer, DNA, Gene Expression, H1N1, H3N2, H5N1, Influenza, Pandemic, Swine Flu, Vaccine, Virus
20. November 2009 04:41
Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced positive results from a recently completed phase II clinical study of its ToleroMune(R) cat allergy therapy, which successfully identified the optimal dosing regimens to progress into late-stage development.
[More]
20. November 2009 00:52
At the annual meeting of the Sexual Medicine Society of North America (SMSNA), Inc. in San Diego, Sciele Pharma, Inc., a Shionogi Company and Plethora Solutions Limited, a wholly owned subsidiary of Plethora Solutions Holdings PLC ("Plethora")., today presented data from its second positive pivotal study of PSD502 for the treatment of premature ejaculation (PE).
[More]
d813dc78-c992-4259-a39a-c277c8bdb0c2|0|.0
Posted in: Men's Health News | Drug Trial News
Tags: Allergy, Angina, Asthma, Cancer, Cholesterol, Cystitis, Diabetes, Erectile Dysfunction, Incontinence, Interstitial Cystitis, Metabolic Syndrome, New Drug Application, Overactive Bladder, Pediatrics, Premature Ejaculation, Sexual Dysfunction, Stress, Type 2 Diabetes, Urinary Incontinence
20. November 2009 00:00
Curemark LLC, (www.curemark.com), a drug research and development company focused on the treatment of neurological diseases, announced that the company has begun enrolling patients in Phase III clinical trials for CM-AT, its autism treatment, at three additional clinical trial sites.
[More]
19. November 2009 10:37
Aegera Therapeutics Inc. announced today the dosing of the first patient in a randomized Phase 2B study of AEG35156, a targeted antisense therapeutic in mid-stage development for multiple oncology indications.
[More]
0f477df3-7276-483a-9f16-5c5e959136a1|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Antisense, Apoptosis, Biotechnology, Cancer, Cell, Chemotherapy, Hepatocellular Carcinoma, Leukemia, Lymphoma, Oncology, Sorafenib
19. November 2009 09:35
Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has expanded its Phase 2 clinical study of a proprietary investigational triple-combination antiviral drug therapy for influenza to include centers in the United States, Canada and Europe. The study, which was initiated in August 2009 in the Southern Hemisphere, is designed to investigate Adamas' triple combination antiviral drug (TCAD) therapy as a treatment for influenza A, including novel influenza A/H1N1, the cause of the current flu pandemic.
[More]
19. November 2009 08:41
Altair Therapeutics, Inc., a privately-held, biopharmaceutical company developing novel therapeutics for respiratory diseases, today announced the commencement of its IL-4 receptor alpha inhibitor bronchoprovocation trial. Study AIR645-CS2 is a phase 2, multi-center, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, and efficacy of inhaled AIR645 in suppressing the asthmatic response in subjects with mild asthma. Results are expected in the third quarter of 2010.
[More]
19. November 2009 08:36
At the annual meeting of the Sexual Medicine Society of North America, Inc. in San Diego, Sciele Pharma, Inc., a Shionogi Company, and Plethora Solutions Limited, a wholly owned subsidiary of Plethora Solutions Holdings PLC, today presented data from its second positive pivotal study of PSD502 for the treatment of premature ejaculation (PE).
[More]
a70e4e7a-e1ac-4c00-9287-42a28bd3aa55|0|.0
Posted in: Men's Health News | Drug Trial News
Tags: Allergy, Angina, Asthma, Cancer, Cholesterol, Cystitis, Diabetes, Erectile Dysfunction, Incontinence, Interstitial Cystitis, New Drug Application, Overactive Bladder, Pediatrics, Premature Ejaculation, Stress, Type 2 Diabetes
19. November 2009 08:11
Geron Corporation today announced the presentation of interim data from its ongoing trial of imetelstat (GRN163L), a telomerase inhibitor drug, in patients with refractory, advanced solid cancers at the 2009 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.
[More]
19. November 2009 05:33
AFFiRiS AG will focus its Alzheimer's vaccine program on one product candidate at an unexpectedly early stage of development: the vaccine candidate AD02 is planned to enter into Phase II clinical trial early in 2010. This decision by the company immediately follows the completion of two Phase I trials with the candidates AD01 and AD02. The company based its fast decision on the first interim analysis of the secondary endpoints at the six month time point.
[More]
19. November 2009 03:50
ImmuPharma PLC the specialist discovery and development pharmaceutical company is pleased to announce today the final results from a Phase IIb trial of LUPUZOR™ in active patients with Systemic Lupus Erythematosus (SLE). Lupuzor™ administered at 200 mcg once-a-month for 3 months plus standard of care achieved a clinically significant improvement in patient response rate as measured by the combined score compared to placebo plus standard of care.
[More]
19. November 2009 03:20
Sangamo BioSciences, Inc. announced today that data from the University of Pennsylvania investigator sponsored Phase 1 safety study of Sangamo's zinc finger nuclease (ZFN) based product, SB-728-T, for HIV/AIDS were inadvertently and prematurely disclosed on the internet.
[More] 
Subscribe